Coronavirus (COVID-19) Collection
Personal Protective Measures during the COVID-19 Pandemic in GermanyThe first case of COVID-19 in Germany was reported on January 27, 2020 (Bavarian State Ministry of Health and Care, 2020). The virus SARS-CoV-2 spreads fast, and within the first two months, more than 42,000 cases had been notified (Robert Koch Institute, 2021). Containment of the virus was not only complicated by the fact that it was found to be contagious even before the onset of symptoms but also because some individuals can live through an infection without showing any symptoms and still infect others (Almadhi et al., 2021; Buitrago-Garcia et al., 2020).
The impact of COVID-19 on health care–associated infections in intensive care units in low- and middle-income countries: International Nosocomial Infection Control Consortium (INICC) findingsBefore the appearance and worldwide spread of the COVID-19 pandemic, a pervasive decrease in health care–associated infection (HAI) incidence had been observed across hospitals in the United States (Weiner-Lastinger et al., 2021b). Throughout 2020, as COVID-19 swept across the United States in multiple waves of infections, regions experienced steep surges in cases and hospitalizations (Ripa et al., 2021). Some studies specifically noted the occurrence of secondary infections in patients with COVID-19 (Ripa et al., 2021).
Country differences in transmissibility, age distribution and case-fatality of SARS-CoV-2: a global ecological analysisObjectives The first COVID-19 pandemic waves in many low-income countries appeared milder than initially forecasted. We conducted a country-level ecological study to describe patterns in key SARS-CoV-2 outcomes by country and region and explore associations with potential explanatory factors, including population age structure and prior exposure to endemic parasitic infections. Methods We collected publicly available data and compared them using standardisation techniques. We then explored the association between exposures and outcomes using random forest and linear regression.
Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysisCoronavirus disease 2019 (COVID-19) is currently one of the most common diseases in the world, and has a considerable death toll (WHO, 2021). Although most patients have mild–moderate clinical manifestations, a significant proportion of patients develop life-threatening complications (Lim et al., 2020; Pranata et al., 2020a, 2021c). Complications caused by coagulopathy are among the most important. Activation of the coagulation pathway and endothelial cells (ECs) is a hallmark of severe COVID-19, which is consistent with high rates of venous thromboembolism (VTE), pulmonary embolism (PE) and disseminated intravascular coagulation (DIC) (Mancini et al., 2021a; Ward et al., 2021).
Evaluation of the AMP SARS-CoV-2 rapid antigen test in a hospital settingThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a broad clinical spectrum known as coronavirus disease 2019 (COVID-19) and was first identified in December 2019 in Wuhan, China (Zhu et al., 2020; Zhou et al., 2020). Within a short time, a worldwide spread led to the current pandemic that will presumably remain the leading infectious disease topic in 2021 (WHO, 2020a).
Usefulness of the COVID-GRAM and CURB-65 scores for predicting severity in patients with COVID-19In December 2019, the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in the city of Wuhan, China (Sohrabi et al., 2020). Spreading around the world in the early part of 2020, this disease outbreak is now considered a pandemic, with more than 45 million cases worldwide and more than 1 100 000 deaths by the end of October 2020, according to the World Health Organization (who.int/emergencies, 2020).
Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label studyCoronavirus disease 2019 (COVID-19) is a global public health emergency (World Health Organization, 2021). Hundreds of millions of people have been infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at the time of writing. Although most patients with COVID-19 are asymptomatic or experience only mild influenza-like illness (Day, 2020), a significant proportion may develop severe pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure (MOF) and death (Lim et al., 2020).
Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimatesRepurposing of available drugs for patients with coronavirus disease 2019 (COVID-19) has gained interest due to the scarcity of drugs proven to be useful in these patients. Dexamethasone, statins, metformin, dipeptidyl peptidase-4 inhibitors and renin–angiotensin system inhibitors have shown clinical benefits for severe and critically ill patients, especially those who are mechanically ventilated (Castiglione et al., 2020; Lim and Pranata, 2020a; Lukito et al., 2020; Pranata et al., 2020c; Rakhmat et al., 2021).
Impact of COVID-19 on vasooclusive crisis in patients with sickle cell anaemiaCOVID-19, caused by SARS-CoV-2 (Gorbalenya et al., 2020), has spread to 191 countries and all continents ( https://coronavirus.jhu.edu/map.html ), and the pandemic shows no signs of coming under control, despite global efforts. The pandemic has resulted in an unprecedented number of deaths globally, with widespread lockdowns and disruption to world economies and businesses (Fauci et al., 2020). The clinical features of SARS-CoV-2 vary from mild in approximately 80% of cases, severe in 15% and critical in 5%.
Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label studyA novel coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 (COVID-19) in a cluster of patients in Wuhan, China, which has been designated a worldwide pandemic (Cucinotta and Vanelli, 2020; Spinelli and Pellino, 2020). As of 31 January 2021, there have been 102,139,771 confirmed cases of COVID-19 worldwide, including 2,211,762 reported deaths (WHO, 2021).
Comparative assessment of mortality risk factors between admission and follow-up models among patients hospitalized with COVID-19The SARS-CoV-2 virus has infected more than 100 million and killed nearly 2.5 million people worldwide over the past few months (JHU, 2020). Although most patients are asymptomatic or have mild symptoms, 10% of them require hospitalization and 5% advanced medical support (Wu and McGoogan, 2020). Early identification of severe cases that will demand longer hospitalizations and increased costs can help guide medical decisions and manage hospital resources, especially in economically deprived areas.
Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospitalThe emergence and rapid spread of the COVID-19 outbreak, caused by SARS-CoV-2, has become a global health emergency and one of our century's greatest challenges. As of February 24, 2021, approximately 111 million confirmed cases and more than 2.4 million deaths had been reported worldwide (Anon, 2020).
Temporal profile of SARS-CoV-2 viral load in posterior nasopharyngeal samples: Analysis of 944 patients in Apulia, ItalyFrom early 2020 a new Coronavirus disease named COVID-19 has spread worldwide with Italy being one of the most affected countries, albeit with substantial regional differences (IstitutoSuperiorediSanità; WHO). In the Apulia region (southern Italy) approximately 7900 cases of COVID-19 infection have been reported so far, with a peak at the end of April and a substantial decrease from May-June. The rate of hospitalization and number of severe cases also fell during this time (IstitutoSuperiorediSanità).
No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19The outbreak of coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization on March 11, 2020. As of June 22, 2020, a total of 2,275,645 COVID-19 cases and 119,923 related deaths had been reported in the United States (Centers for Disease Control and Prevention, 2020). Reports from around the world indicate that this disease will continue to spread with the potential to cause severe illness in 10%–20% of those infected and to lead to hospitalization, ICU admission, ventilator support, and death.
Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-AnalysisWhat is known What is new
Spread of COVID-19 and policy responses in Vietnam: An overviewThe coronavirus disease 2019 (COVID-19) pandemic has spread rapidly across the globe since December 2019. As of 26 October 2020, more than 43.5 million COVID-19 confirmed cases have been reported, with almost 1.2 million associated deaths (Johns Hopkins University, 2020). Furthermore, the number of confirmed cases is still increasing rapidly in many countries (World Health Organisation, 2020).
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trialA novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2), emerged in late December 2019, which resulted in the ongoing worldwide coronavirus disease 2019 (COVID-19) pandemic (World Health Organization, 2020; Zhou et al., 2020 Zhou et al., 2020). As of September 25, 2020, the Johns Hopkins University COVID-19 global dashboard reports 32,390,204 confirmed cases and 985,302 deaths worldwide attributed to SARS-CoV-2 (The Center for Systems Science and Engineering at Johns Hopkins, 2020).
Pandemic risk of COVID-19 outbreak in the United States: An analysis of network connectedness with air travel dataThe United States has become the country with the largest number of COVID-19 reported cases and deaths. This study aims to analyze the pandemic risk of COVID-19 outbreak in the US.
Spatial variability in reproduction number and doubling time across two waves of the COVID-19 pandemic in South Korea, February to July, 2020Since the first COVID-19 cases were reported in Wuhan, Hubei Province, China in December 2019, more than 24.7 million cases of coronavirus disease (COVID-19), including more than 830 000 related deaths, had been reported worldwide (WHO) as of August 30, 2020. In South Korea, the novel coronavirus was first diagnosed in a 36-year-old Chinese woman who entered the country on January 20, 2020. South Korea has since experienced two heterogeneous waves of the disease, with a total of 13 745 cases, including 295 deaths, as of July 19, 2020 (KCDC, 2020a).
Estimation of the probable outbreak size of novel coronavirus (COVID-19) in social gathering events and industrial activitiesThe outbreak of COVID-19 has currently spread to more than 217 territories (Hui et al., 2020) since December 2019 (Chang et al., 2020; Li et al., 2020; Roda et al., 2020; Wu et al., 2020). According to the latest statistics, up to May 1, 2020, there have been more than 3,389,933 confirmed cases found in more than 187 countries covering six continents (Johns Hopkins Coronavirus Resource Center, 2020). COVID-19 was officially declared by the World Health Organization (WHO) a pandemic on March 29, 2020 (WHO, 2020).
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19As of May 27, 2020, there were over 1,678,843 confirmed cases of COVID-19 claiming more than 100,000 lives in the Unites States (CDC, 2020). Currently there is no known effective therapy or vaccine. The urgent need for therapeutic agents has resulted in repurposing and redeployment of experimental agents (McCreary and Pogue, 2020; Sanders et al., 2020).
COVID-19 outbreak in Malaysia: Actions taken by the Malaysian governmentThe world is currently experiencing a deadly infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), called coronavirus disease 2019 (COVID-19). The Director General of the World Health Organization (WHO), Dr. Tedros Adhanom Ghebreyesus, in his opening remarks at the media briefing on COVID-19 on April 10, 2020, announced that the COVID-19 outbreak had affected 213 countries, with 1,524,162 confirmed positive cases and 92,941 deaths. COVID-19 is caused by a novel coronavirus (SARS-CoV-2) that infects the respiratory tract.
Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samplesSince the first reported cases in December 2019, the rapidly emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been causing tremendous public health challenges worldwide (WHO, 2020a). Timely detection and isolation of cases and their contacts are considered crucial to help curtail this unprecedented pandemic (Nguyen et al., 2020). This strategy relies on robust, rapid, and easy-to-perform diagnostic tools that can be used to test large numbers of samples in a short period of time.
Addressing the corona virus pandemic: will a novel filtered eye mask help?The 2019 novel coronavirus (COVID-19) originated in Wuhan City, Hubei Province, China with clinical manifestations similar to those of the severe acute respiratory syndrome (SARS) outbreak in 2003 (Huang et al., 2020, Li et al., 2020, Phan et al., 2020). In a matter of months, the COVID-19 outbreak has rapidly evolved into a global pandemic. At the time of writing this, COVID-19 has infected over 2,000,000 people and has claimed the lives of over 125,000, with the numbers growing daily (Worldometer, 2020).
Epidemic update of COVID-19 in Hubei Province compared with other regions in ChinaSince the first atypical pneumonia case, caused by a novel coronavirus was reported in Wuhan, China on December 31, 2019 (WHO, 2020a), the novel coronavirus infection outbreak quickly spread in Wuhan, the capital of Hubei Province and other districts of Hubei Province with a further spread across the Chinese mainland. By 29 Feb 2020 a total of 79,824 cases of infection had been confirmed nationwide including all administrative regions, with another 851 suspected cases. COVID-19 cases were also reported in Thailand, Japan, the Republic of Korea, Hong Kong, Taiwan, the US, and some countries in Europe (CCDCPC, 2019).